Published in J Mol Histol on February 01, 2005
The osteocyte: an endocrine cell ... and more. Endocr Rev (2013) 1.84
Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res (2009) 1.84
Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord (2010) 1.64
Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2. J Bone Miner Res (2008) 1.53
Control of RANKL gene expression. Bone (2009) 1.47
Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone (2012) 1.40
Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response. Osteoporos Int (2008) 1.39
Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res (2012) 1.29
Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. Epigenetics (2012) 1.26
Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr (2012) 1.18
The effect of n-3 fatty acids on bone biomarkers in Iranian postmenopausal osteoporotic women: a randomized clinical trial. Age (Dordr) (2009) 1.11
Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development. BMC Genomics (2007) 1.10
Commitment to the osteoblast lineage is not required for RANKL gene expression. J Biol Chem (2009) 1.05
C-type natriuretic peptide regulates endochondral bone growth through p38 MAP kinase-dependent and -independent pathways. BMC Dev Biol (2007) 1.03
Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. J Bone Miner Metab (2008) 1.01
Osteocyte apoptosis is required for production of osteoclastogenic signals following bone fatigue in vivo. Bone (2014) 0.94
Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone (2014) 0.92
Chondrocyte β-catenin signaling regulates postnatal bone remodeling through modulation of osteoclast formation in a murine model. Arthritis Rheumatol (2014) 0.91
Pharmacological management of osteogenesis. Clinics (Sao Paulo) (2014) 0.85
RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol (2008) 0.83
Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association. Bone (2015) 0.81
Effects of cyclic hydraulic pressure on osteocytes. Bone (2010) 0.81
Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone. Sci Rep (2015) 0.81
Imbalance of RANK, RANKL and OPG expression during tibial fracture repair in diabetic rats. J Mol Histol (2008) 0.78
β-catenin activity in late hypertrophic chondrocytes locally orchestrates osteoblastogenesis and osteoclastogenesis. Development (2016) 0.78
Effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins. J Mol Histol (2007) 0.78
Tartrate-resistant acid phosphatase (TRAP) co-localizes with receptor activator of NF-KB ligand (RANKL) and osteoprotegerin (OPG) in lysosomal-associated membrane protein 1 (LAMP1)-positive vesicles in rat osteoblasts and osteocytes. Histochem Cell Biol (2014) 0.78
Paradoxical response to mechanical unloading in bone loss, microarchitecture, and bone turnover markers. Int J Med Sci (2015) 0.78
The Modulatory Effects of Mesenchymal Stem Cells on Osteoclastogenesis. Stem Cells Int (2015) 0.75
Mitogen-inducible gene-6 partly mediates the inhibitory effects of prenatal dexamethasone exposure on endochondral ossification in long bones of fetal rats. Br J Pharmacol (2016) 0.75
Comparison of the effects of canola oil versus sunflower oil on the biochemical markers of bone metabolism in osteoporosis. J Res Med Sci (2012) 0.75
Wnt/β-catenin Signaling in Osteoarthritis and in Other Forms of Arthritis. Curr Rheumatol Rep (2017) 0.75
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res (2000) 3.38
Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2001) 2.93
A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology (1998) 1.75
Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone (1999) 1.66
Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem (2000) 1.39
The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum (2001) 1.28
Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res (2001) 1.13
Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand. J Bone Miner Res (2000) 1.11
In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res (2000) 0.97
Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation. Bone (2000) 0.84
Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis (2003) 0.80
Clonal endothelial cells produce humoral factors that inhibit osteoclast-like cell formation in vitro. Endocr J (2002) 0.78
Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. J Histochem Cytochem (2002) 0.78
The multitasking role of macrophages in Stanford type A acute aortic dissection. Cardiology (2013) 2.66
PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis (2002) 1.68
Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant (2002) 1.42
Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum (2006) 1.31
Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing. Cancer Res (2011) 1.16
Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA(Ile) mutation causing hypertrophic cardiomyopathy. Hum Mol Genet (2011) 1.09
MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol (2012) 1.07
Comment on "Influence of HLA-C expression level on HIV control". Science (2013) 1.07
Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia (2011) 1.06
High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med (2011) 1.04
Induction of non-alcoholic fatty liver disease and insulin resistance by feeding a high-fat diet in rats: does coenzyme Q monomethyl ether have a modulatory effect? Nutrition (2009) 1.02
Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol (2010) 0.99
PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. Diagn Mol Pathol (2009) 0.98
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats. Clin Sci (Lond) (2009) 0.96
Risk factors of one year increment of coronary calcifications and survival in hemodialysis patients. BMC Nephrol (2010) 0.95
Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis. Am J Nephrol (2007) 0.93
HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. J Immunol (2008) 0.93
Dacarbazine treatment before peptide vaccination enlarges T-cell repertoire diversity of melan-a-specific, tumor-reactive CTL in melanoma patients. Cancer Res (2010) 0.93
Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron (2002) 0.91
Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol (2011) 0.91
Heat-shock protein 90: a novel autoantigen in human carotid atherosclerosis. Atherosclerosis (2009) 0.91
Thyroid hormones induce cell proliferation and survival in ovarian granulosa cells COV434. J Cell Physiol (2009) 0.91
Neuroendocrine tumors of the gallbladder: a case report and review of the literature. J Med Case Rep (2011) 0.89
A single bottleneck in HLA-C assembly. J Biol Chem (2007) 0.89
T and NK cells: two sides of tumor immunoevasion. J Transl Med (2013) 0.89
Atherosclerotic ischemic renal disease. Diagnosis and prevalence in an hypertensive and/or uremic elderly population. BMC Nephrol (2003) 0.87
Serum leptin in dialysis renal osteodystrophy. Am J Kidney Dis (2003) 0.87
Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. Nanoscale (2013) 0.86
25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int (2005) 0.86
Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells. J Immunol (2009) 0.85
Atherosclerotic renal artery stenosis: one year outcome of total and separate kidney function following stenting. BMC Nephrol (2004) 0.83
Salivary cortisol, dehydroepiandrosterone-sulphate (DHEA-S) and testosterone in women with chronic migraine. J Headache Pain (2006) 0.82
Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Am J Kidney Dis (2006) 0.82
Osteopetrosis complicated by osteomyelitis of the maxilla and mandible: light and electron microscopic findings. Head Neck Pathol (2009) 0.82
Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer. Clin Chim Acta (2013) 0.81
Cross-talk between NO and HMGB1 in lymphocytic thyroiditis and papillary thyroid cancer. Oncol Rep (2010) 0.81
Experimental pharmacology of glucosamine sulfate. Int J Rheumatol (2011) 0.80
Expression of phosphoinositide-specific phospholipase C enzymes in normal endometrium and in endometriosis. Fertil Steril (2012) 0.80
OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST. J Mol Histol (2007) 0.80
Fibroblast growth factor acts upon the transcription of phospholipase C genes in human umbilical vein endothelial cells. Mol Cell Biochem (2013) 0.79
N-linked glycosylation selectively regulates the generic folding of HLA-Cw1. J Biol Chem (2008) 0.78
Correlation of the Rac1/RhoA pathway with ezrin expression in osteosarcoma. Appl Immunohistochem Mol Morphol (2014) 0.78
Expression of Phosphoinositide-specific phospholipase C enzymes in human osteosarcoma cell lines. J Cell Commun Signal (2013) 0.78
Asymmetric dimethylarginine, vascular calcifications and parathyroid hormone serum levels in hemodialysis patients. J Nephrol (2009) 0.78
A review of phosphate mineral nucleation in biology and geobiology. Calcif Tissue Int (2013) 0.78
Effects of the administration of corticosterone, parathyroid hormone, or both, and of their withdrawal, on rat bone and cartilage histomorphometric parameters, and on osteoprotegerin and RANKL mRNA expression and proteins. J Mol Histol (2007) 0.78
[The role of intraoperative parathyroid hormone assay in the surgical management of hyperparathyroidism]. Ann Ital Chir (2007) 0.77
Bone disease in long-term renal transplant recipients with severe osteopenia: a cross-sectional study. Transplantation (2006) 0.76
Immunohistochemical localization and mRNA expression of matrix Gla protein and fetuin-A in bone biopsies of hemodialysis patients. Virchows Arch (2009) 0.76
The KIT Exon 11 Stop Codon Mutation in Gastrointestinal Stromal Tumors: What Is the Clinical Meaning? Gut Liver (2012) 0.75
HLA-E and the origin of immunogenic self HLA epitopes. Mol Immunol (2010) 0.75
Programmable interactions of functionalized single bioparticles in a dielectrophoresis-based microarray chip. Anal Chem (2013) 0.75
In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis. Artif Organs (2004) 0.75
The possible role of the transcription factor nuclear factor-κB on evolution of rotator cuff tear and on mechanisms of cuff tendon healing. J Shoulder Elbow Surg (2012) 0.75